Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.

Employees - 26, CEO - Amro A. Albanna, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -35.9, Piotroski Score(max is 10): 2, Working Capital: $-12491562, Total Assets: $13906812, Retained Earnings: $-225756495, EBIT: -50941885, Total Liabilities: $49081198, Revenue: $14336

- Current Price $ - Analyst Target Price $